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Abstract
Background: People with Parkinson’s (PwP) experience frequent and recurrent falls. As these falls may have
devastating consequences, there is an urgent need to identify cost-effective interventions with the potential to
reduce falls in PwP. The purpose of this economic evaluation is to compare the costs and cost-effectiveness of a
targeted exercise programme versus usual care for PwP who were at risk of falling.
Methods: One hundred and thirty participants were recruited through specialist clinics, primary care and
Parkinson’s support groups and randomised to either an exercise intervention or usual care. Health and social care
utilisation and health-related quality of life (EQ-5D) were assessed over the 20 weeks of the study (ten-week
intervention period and ten-week follow up period), and these data were complete for 93 participants. Incremental
cost per quality adjusted life year (QALY) was estimated. The uncertainty around costs and QALYs was represented
using cost-effectiveness acceptability curves.
Results: The mean cost of the intervention was £76 per participant. Although in direction of favour of exercise
intervention, there was no statistically significant differences between groups in total healthcare (−£128, 95% CI:
-734 to 478), combined health and social care costs (£-35, 95% CI: -817 to 746) or QALYs (0.03, 95% CI: -0.02 to 0.03)
at 20 weeks. Nevertheless, exploration of the uncertainty surrounding these estimates suggests there is more than
80% probability that the exercise intervention is a cost-effective strategy relative to usual care.
Conclusion: Whilst we found no difference between groups in total healthcare, total social care cost and QALYs,
analyses indicate that there is high probability that the exercise intervention is cost-effective compared with usual
care. These results require confirmation by larger trial-based economic evaluations and over the longer term.
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Background
Parkinson’s is a progressive neurodegenerative disorder
that mainly affects older individuals. The prevalence
rates of Parkinson’s are estimated at 1 per cent in people
aged over 60 years and between 0.15 and 0.3 per cent in
the general population with a mean age of onset in the
mid sixties [1]. Cost of illness studies have shown that
Parkinson’s is costly for individuals, the health-care sys-
tem and society more broadly [2,3]. Hospitalisation and
drug therapy account for more than sixty percent of the
direct costs associated with Parkinson’s [4]. Annual UK
expenditure is in excess of £1.4 billion taking account of
health and social care, loss of productivity and informal
care costs [5] with costs increasing as the condition pro-
gresses [6].
PwP experience frequent and recurrent falls. As many
as 65 percent of fallers will experience an injury second-
ary to falling, of whom 33 percent will sustain a fracture
[7]. Although cost of illness studies have not quantified
the costs of falls and fall-related injuries for those with
Parkinson’s, it estimated that as much as 75 percent of
falls result in additional health care utilisation and asso-
ciated costs [8]. Moreover, the fear of falling results in
restriction of activities of daily living and can markedly
compromise health-related quality of life (HRQoL) [9].
Any intervention that reduces falls in PwP might there-
fore be expected to have important impact on costs and
HRQoL.
A systematic review of exercise interventions aimed at
PwP reported a paucity of studies in relation to falls
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prevention, with no studies to date examining the costs
or cost-effectiveness of any interventions aimed at pre-
venting falls in PwP [10]. There have, however, been
reviews of economic evaluations of fall prevention inter-
ventions targeting older people that indicate the cost ef-
fectiveness of exercise interventions [11], home safety
modifications for those at high risk of falling and multi-
factorial assessments with targeted interventions [12].
A pragmatic randomised controlled trial (GETuP) was
recently undertaken to assess the effectiveness of a tar-
geted exercise programme in PwP who have a history of
falling [13]. Although no significant difference in the rate
of falls was observed in those undertaking a 10 week ex-
ercise intervention compared with usual care controls,
the exercise group did experience superior gains in Berg
balance, Falls Efficacy Scale-International scores and rec-
reational physical activity levels [13].
In the present paper we describe an economic evalu-
ation undertaken alongside the GETuP trial. This eco-
nomic evaluation aimed to assess the costs of the
provision of an exercise intervention for the prevention
of falls in PwP and whether this intervention was cost-
effective in terms of quality adjusted life years (QALYs).
Methods
Full details of the trial design, participants, interventions,
and outcome assessments are described elsewhere [13].
Ethical approval was obtained from the Devon and Tor-
bay Research Ethics committee (07/Q2102/8) and writ-
ten informed consent was provided by all participants.
In summary, participants were recruited through special-
ist clinics, primary care and Parkinson’s support groups
in the South West of England between May 2007 and
November 2008. A total of 130 participants with a diag-
nosis of Parkinson’s and self-reported history of two or
more falls in the preceding 12 months were randomised
to either participate in a ten-week group exercise
programme with supplementary home exercises (inter-
vention group, n=64) or to continue with usual care
alone (control group, n=66). Both groups were assessed
at baseline (prior to randomisation) and at 20 weeks
(following ten-week intervention period plus a ten-
week follow up period). The intervention comprised
once weekly group exercise sessions, with twice weekly
home strength and balance training exercises, commen-
cing ten weeks after the baseline assessment. For each
group, sessions were delivered in community settings,
National Health Service physiotherapists, with experi-
ence of working with older people and those with
Parkinson’s. The size of the groups was set at a max-
imum of six participants due to space restrictions at
some venues, and also for reasons of safety and
group management [14]. All participants received usual
care that could include medical and medication
management, physiotherapy (e.g., exercise, advice, pro-
vision of walking aids, gait training), occupational ther-
apy (e.g., modification of home hazards, provisions of
aids or adaptations) or speech therapy.
For the purposes of this economic analysis, we mea-
sured costs from the perspective of UK National Health
Service and Personal Social Services. A cost utility ana-
lysis was performed: both groups were analysed for their
differences in total costs compared with differences in
QALYs. The study was conducted and reported in ac-
cordance with health economics reporting guidelines
[15].
Assessment of health outcome
The health status of participants was assessed using the
EQ-5D (or EuroQol), a generic and validated measure of
choice for which reliable UK population preference
values are available [16]. The EQ-5D measures health on
five domains (mobility, self-care, usual activities, pain–
discomfort, and anxiety–depression), and the scores
were combined to generate a single utility value. Pub-
lished utility values for the EQ-5D range from 1.00 for
the ‘best health’ state to −0.594 for the ‘worst health’
state, where a score of 0 is regarded as equivalent to
death, and scores less than 0 are considered as ‘worse
than death’ [17]. Participants completed the EQ-5D at
baseline and 20 weeks. During this follow-up, partici-
pants were assessed twice: first following a ten-week
group exercise intervention (post-intervention), and then
again at 10 weeks follow-up. Participants who died dur-
ing the study were registered as zero in utility terms for
the assessment period from when the death occurred.
We calculated the number of QALYs gained or lost over
the 20 weeks of follow up using the area under the
curve, and we assumed a linear change in utility between
measurement points [18,19].
Quantifying use of resources
The time and grade of physiotherapists involved in the
delivery of the exercise intervention was recorded via
records kept by the research team together with the cost
of venue hire, equipment costs and travel costs incurred
by physiotherapists and participants. Travel costs were
calculated on distance travelled from participant’s home
(or physiotherapist’s base) to the exercise venue based
on postcodes [20]. We calculated the average interven-
tion cost per participant assuming all participants rando-
mised to the intervention group (n=64) attended all of
the exercise classes [13].
At each follow up visit, participants reported their use
of Parkinson’s medication (type and dose). The number
of hospital contacts, primary-care and social service con-
tacts were obtained for each participant using routine
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databases from local hospital Trusts, general practices
and Devon County Council Social Services.
Costs
In order to translate medication and health and social
service resource use into monetary values, unit costs or
prices were applied [15,21,22]. Resources were valued
using both local or national costs and prices (Table 1).
Staff costs included indirect overheads (the costs of sup-
port services such as human resources, finance, and
estates needed to carry out the service’s main functions)
and building capital (the costs assigned to intervention
space). All unit costs were calculated for the financial
years 2008/9.
Data analysis and statistical methods
Intervention and control groups were compared at fol-
low up, based on randomised allocation. Health and so-
cial care contacts were analysed using logistic and
Poisson regression and expressed as rate and risk ratios
and their associated 95% confidence intervals (CIs). Al-
though costs were not normally distributed, analyses
compared the mean costs in the two groups using the
student’s t-test with ordinary least squares regression
used to adjust the between group comparison for base-
line costs. Parametric statistical analysis allowed us to
Table 1 Unit costs for health and social care resource use
Resource item† Cost Basis of estimate
Primary care
General Practitioner (GP)
surgery appointments
£36.00 An 11.7 minute consultation
General Practitioner (GP)
home visits
£58.00 A 23.4 minute visit
Practice nurse (PN)
surgery appointments
£11.00 A consultation
Community/district nurse
(CN) visits
£26.00 A home visit
Hospital-based care
*Acute hospital bed days £213.20 A bed day of inpatient
rehabilitation for an elderly
person (£205 inflated by 1.04)
Day admissions £138.00 A day care service attendance
for an elderly person
Accident & Emergency
(A&E) attendances
£111.00 An A&E treatment
Minor Injury Unit (MIU)
attendances
£35.00 An attendance at a non 24-hour
A&E department/Casualty
department
Outpatient consultant
appointments
£55.00 A first-attendance appointment
£71.00 A follow-up attendance
appointment
^Parkinson’s Disease
specialist nurse
(PDNS) appointments
£15.00 A 15 minute consultation (using
‘Nurse advanced [includes
lead specialist, clinical nurse
specialist, senior specialist])
^Parkinson’s Disease
specialist nurse (PDNS)
visits
£16.66 A 25 minute home visit (using
‘Nurse advanced [includes lead
specialist, clinical nurse specialist,
senior specialist]) at £40/hour
Social care
Social worker/community
care manager assessments
£414.00 An hour of face-to-face
contact = £138 Average length
of contact (from DCC info
provided to QAQoL) = 3hours
Hours of home care
(per hour)
£19.30 One hour of local authority
organized home care
Hours of day care
(per hour)
£11.66 A session = £35
Estimated 3 hours per session
Days of residential care
(per day)
£136.86 Local authority care package
for a short-term resident
week = £958
Days of nursing care
(per day)
£93.71 Private care package cost
for a short-term resident
week = £656
† The unit costs of resource items were identified using 2008 cost data from
the Personal Social Services Research Unit (Curtis, 2008).
* No 2008 cost data were available for acute hospital bed days, so the PSSRU
2007 cost was inflated for this item (Curtis, 2007).
^ No unit cost data were available for PDNS care, so the PSSRU 2008 costs for
a ‘Nurse advanced (includes lead specialist, clinical nurse specialist, senior
specialist) were used, as these relate to the same NHS pay band (Band 7) as
PDNS, quoted by NICE 2006.
Table 2 Comparison of baseline characteristics for
participants with missing and available economic data
Available
(N=93)
Missing
(N=37)
Age in years mean (SD) 71.0 (8.8) 71.1 (7.7)
Male (%) 48 (52%) 26 (70%)
Years since diagnosis of PD mean (SD) 8.8 (6.5) 8.3 (6.2)
Hoehn and Yahr stage Mean (SD) 2.5 (0.9) 2.6 (0.9)
Living arrangements n (%)
Alone 21 (23%) 12 (32%)
With partner 68 (73%) 24 (65%)
With family/friends 2 (2%) 1 (3%)
Residential home 2 (2%) 0 (0%)
Parkinson’s medication n (%)
LCT 88 (95%) 36 (97%)
DRA 46 (49%) 18 (49%)
MOAI 16 (17%) 6 (16%)
Co-morbidity n (%)
Orthopaedic 31 (33%) 15 (41%)
Cardiac 30 (32%) 16 (43%)
EQ-5D mean (SD) 0.67 (0.23) 0.68 (0.25)
Total healthcare costs in previous
10 weeks (£) mean (SD)+
142 (227) 768 (481)
+ Primary and secondary care costs - data only available in 115 individuals
(90/25).
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make inferences about mean costs [23]. Ninety five per-
cent CIs for mean difference in costs were calculated
using the non-parametric bias corrected bootstrapping
method (1000 replications) [15]. As there were no differ-
ences in inferences between unadjusted (for baseline
values) and adjusted models, we report only unadjusted
results here.
Cost-effectiveness is concerned with the joint differ-
ence in costs and outcome between interventions and
was assessed over the 20 week period (i.e. ten-week
intervention period combined with the ten-week follow-
up period) through the calculation of an incremental
cost-effectiveness ratio (ICER) [24]. The ICER is the
ratio of differential average costs of the intervention and
control group to the differential QALYs.
Repeat re-sampling from the costs and QALY data
(bootstrapping) was used to generate a distribution of
mean costs and QALYs for the two participant groups
[25]. These distributions are used to calculate the prob-
ability that intervention or control is the optimal choice,
Table 3 Health care resource utilisation at 20 weeks
Intervention (n=48) Control (n=45) Effect size (95% CI), P-value
Parkinson’s medication
LCT n/N (%) 42/45 (91%) 38/41 (93%) Relative risk −0.96 (0.86to 1.08), 0.524
GA n/N (%) 1/46 (2%) 3/42 (7%) Relative risk 0.32 (0.03 to 2.96), 0.315
AC n/N (%) 0/47 (0%) 1/44 (2%) Not calculable
CTI n/N (%) 1/47 (2%) 3/42 (7%) Relative risk 0.31 (0.03 to 2.89), 0.306
DRA n/N (%) 19/45 (42%) 17/42 (40%) Relative risk 1.04 (0.63 to 1.72), 0.869
MOBI n/N (%) 4/46 (9%) 5/43 (12%) Relative risk 0.75 (0.21 to 2.60), 0.648
Primary care contacts
GP appointments, mean (SD) 2.19 (3.05) 1.96 (2.58) Rate ratio 1.12 (0.84 to 1.48), 0.438
GP home visits, mean (SD) 0.08 (0.28) 0.09 (0.29) Rate ratio 0.92 (0.23 to 3.66), 0.902
PN appointments., mean (SD) 0.83 (1.17) 0.84 (1.42) Rate ratio 0.99 (0.63 to 1.56), 0.984
CN home visits, mean (SD) 0.04 (0.19) 0.23 (0.99) Rate ratio 0.15 (0.02 to 1.28), 0.084
Acute healthcare contacts
Hospitalisations, mean (SD) 0.06 (0.24) 0.33 (0.74) Rate ratio 0.19 (0.05 to 0.65), 0.008
Inpatient bed days, mean (SD)* 0.50 (3.18) 1.51 (6.30) Mean difference −1.01 (−3.04 to 1.02), 0.326
Day cases, mean (SD) 0.02 (0.14) 0.11 (0.38) Rate ratio 0.19 (0.02 to 1.60), 0.126
A&E attendances, mean (SD) 0.10 (0.37) 0.16 (0.56) Rate ratio 0.67 (0.21 to 2.11), 0.493
Outpatient consultant
Appointments, mean (SD) 2.25 (2.14) 2.69 (2.79) Rate ratio 0.84 (0.65 to 1.08), 0.178
PDNS appointments, mean (SD) 0 (0) 0.02 (0.15) Not calculable
PDNS home visits, mean (SD) 0 (0) 0 (0) Not calculable
Social care contacts
Social/community care assessments 0.17 (0.52) 0.04 (0.21) Rate ratio 3.74 (0.80 to 17.63), 0.095
Home care received, n/N (%) 2/45 (4%) 1/48 (2%) Relative risk 1.88 (0.17 to 19.97), 0.60
Hours of home care, mean (SD) † 9.15 (45.9) 2.00 (13.42) Mean difference 7.14 (−7.00 to 21.29), 0.318
Day care received, n/N (%) 1/47 (2%) 0/45 (0%) Not calculable
Hours of day care, mean (SD)** 0.42 (2.91) 0 (0) Mean difference 0.42 (−0.44 to 1.29), 0.331
Residential care received, n/N (%) 1/44 (2%) 0/48 (0%) Not calculable
Hours of residential care, mean (SD) 0 (0) 0.44 (2.98) Mean difference −0.44 (1.30 to 0.41), 0.304
Nursing care relieved, n/N (%) 1/44 (2%) 0 (0) 0/48 (0%) 0.44 (2.98) Not calculable
Mean difference −0.44 (1.30 to 0.41), 0.304
Hours of nursing care, mean††
* Number of bed days in those with a hospital admission.
† Number of hours of home care in those with a home care visit.
** Number of residential care days in those in residential care.
†† Number of nursing care days in those who received nurse care.
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subject to a range of possible maximum monetary
values (ceiling ratio, λ) that a decision-maker might be
willing to pay for an increase in QALYs. These probabil-
ities are presented as cost-effectiveness acceptability
curves [19] and a judgement made cost-effectiveness on
the basis of maximum willingness to pay threshold of
£20,000 per QALY, (lower boundary of acceptable cost
effectiveness of the National Institute for Health and
Clinical Excellence) [15,26]. These curves incorporate
the uncertainty that exists around the estimates of
mean costs and effects as a result of sampling variation
with uncertainty regarding the maximum cost-
effectiveness ratio that a decision-maker would consider
acceptable.
The impact of missing QALY and cost data were
assessed by comparing the baseline characteristics of
participants who had missing data with those partici-
pants who had full economic data. In addition we under-
took sensitivity analysis to examine the impact of the
cost-effectiveness analysis of missing QALY and cost
data using two approaches to data imputation i.e. last
value carried forward and assumed ‘missing at random’
using multiple imputation by chained equations [27].
The time horizon of the analysis did not require dis-
counting of QALYs or costs. All analyses were under-
taken in Stata v1 (Stata Corp, College Station, Texas).
Results
Of the 130 participants who were randomised, 37 were
excluded from the economic analysis due to missing
resource-use or EQ-5D data. Thus, 93 participants had
complete data on total resource costs and QALYs over
the 20 week follow-up period and were entered into the
economic evaluation (48 intervention group participants,
45 control group participants). A comparison of baseline
characteristics revealed some significant differences be-
tween those included in the economic evaluation and
those for whom data were missing (Table 2). Those
participants with missing data were significantly more
likely to be male and had significantly higher healthcare
costs during the baseline data collection period (the
ten weeks immediately prior to the commencement of
the intervention). However, there was no difference in
missing data between intervention and control.
Exercise intervention costs
The total cost to deliver the 10 week exercise interven-
tion was £4,883 (venue hire: £448; physiotherapist time:
£3,900; physiotherapist travel: £335; equipment: £200)
and corresponded to an average cost of £76 per partici-
pant. This average cost assumed that all participants
attended the intervention and was based on an average
of approximately 4 participants per exercise group.
However, if the maximum group size of six participants
had been achieved this average cost could be reduced to
£54 per participant. The mean participant travel cost in
attending the intervention sessions was £20 (standard
deviation: £2).
Table 4 Healthcare costs at 20 weeks
Intervention
Mean (SD),
median
N=48
Control
Mean (SD),
median
N=45
Mean
difference
(95% CI)
P-value
Parkinson’s medications (£)
Mean (SD) 836 (994),
579
707 (812),
331
129 (−490 to 233),
0.50
Acute healthcare (£)
Inpatient bed days,
mean (SD)
107 (678),
0
322 (1339),
0
−215 (−643 to 212),
0.324
Day case, mean (SD) 3 (20),
0
15 (53),
0
−12 (−30 to 5),
0.156
A&E attendances,
mean (SD)
12 (41),
0
17 (62),
0
−6 (−28 to 17),
0.616
Outpatient consultant
appointments,
mean (SD)
142 (19),
126
169 (26),
162
−28 (−92 to 36),
0.398
PDNS appointments,
mean (SD)
0 (0),
0
1 (2),
0
1 (−1 to 1),
0.321
PDNS home visits,
mean (SD)
0 (0),
0
0 (0),
0
Not calculable
Total acute healthcare,
mean (SD)
263 (749),
126
524 (1429),
126
−389 (−741 to 190),
0.27
Primary healthcare contacts (£)
GP appointments,
mean (SD)
79 (110),
36
70 (93),
36
8 (−31 to 48),
0.677
GP home visit,
mean (SD)
5 (16),
0
5 (17),
0
0 (−7 to 6),
0.923
Parkinson nurse
appointments,
mean (SD)
9 (13),
0
9 (15),
0
0 (−5 to 6),
0.901
Community nurse
home visit, mean (SD)
1 (4),
0
3 (20),
0
−3 (−9 to 3),
0.324
Total primary
healthcare,
mean (SD)
93 (116),
69
88 (101),
62
5 (−38 to 49),
0.80
Social care contacts (£)
Social/community
care assessments,
mean (SD)
70 (217),
0
18 (86),
0
52 (−15 to 119),
0.126
Hours of home care,
mean (SD)
177 (886),
0
39 (259),
0
138 (−129 to 405),
0.312
Hours of day care,
mean (SD)
5 (34),
0
0 (0),
0
5 (−5 to 15),
0.324
Days of residential care,
mean (SD)
0 (0),
0
61 (408),
0
−61 (−173 to 52),
0.290
Days of nursing care,
mean (SD)
0 (0),
0
42 (279),
0
−42 (−123 to 40),
0.318
Total social care,
mean (SD)
252 (1023),
0
159 (753),
0
92 (−268 to 453),
0.62
PDNS: Parkinson specialist nurse.
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Health and social care service resource use
Table 3 details the mean healthcare utilisation across
both groups. Use of medication, and of primary and sec-
ondary care services was compared and no significant
differences were observed.
Health and social care service costs
Table 4 details the cost analyses. Mean total acute
healthcare cost per participant in the intervention group
was £263, on average £389 per participant lower than
for controls. This cost difference was mainly due to a
lower cost of inpatient bed days in the intervention
group. In contrast, social care costs were higher by £97
per participant for the intervention arm due to higher
levels of social care assessment and home care. As
shown in Table 4 none of the between group differences
in total or subtotal costs (e.g. medication, acute health-
care contacts) were statistically significant.
HRQoL, QALYs and cost-effectiveness analysis
The EQ-5D scores used to calculate QALYs are sum-
marised in Table 5. There was no statistically significant
gain in average QALYs from baseline to follow up for
intervention group participants compared to controls
(0.03, 95% CI: -0.02 to 0.08)., The ICER for total health-
care costs was approximately -£4,900 per QALY and the
ICER for combined total healthcare and social care costs
was approximately -£1,400 per QALY (Table 6). Al-
though both ICERs indicate that the intervention is
likely to be dominant compared to control i.e. cheaper
and more effective, the between group differences in
costs and QALYs were not statistically significant.
Figure 1 illustrates the uncertainty associated with
the ICERs and demonstrates that, for values of £0 to
£100,000, the intervention has a higher probability of
being cost-effective than control. The probability of
intervention being more cost effective at £20,000 was
85% when considering total healthcare costs and 81%
for combined healthcare and social care costs. Con-
clusions did not change with the use of imputed full
sample data. Approximate ICERs for the full imputed
sample were -£15,500/QALY (last observation carried
forward) and -£6,000/QALY (multiple imputation) for
total healthcare costs and -£3,900/QALY (last obser-
vation carried forward) and -£3,100/QALY (multiple
imputation) for combined social and healthcare costs.
Discussion
Study findings
This study found no statistically significant between
group differences in total health care costs, combined
health and social care costs or QALYs at 20 weeks fol-
low-up. However, the 95% CIs around these estimates
are wide, suggesting that our analysis may be underpow-
ered to detect such differences. The presentation of
cost-effectiveness acceptability curves are important
within this context, demonstrating that there was over
an 80% probability that the exercise intervention is a
more cost effective option at willingness to pay of
£20,000/QALY. Assuming participation by all interven-
tion participants in the exercise classes (n=64), the aver-
age healthcare cost of the 10 week exercise intervention
was £76 per participant, although this could potentially
be reduced to £54 per participant if the maximum par-
ticipant:staff ratio of 6:1 had been achieved.
Comparisons with previous literature
Although no studies have examined the costs and cost-
effectiveness of exercise programmes aimed at prevent-
ing falls in PwP, a small number have examined this
issue in community-dwelling elderly populations [28-30].
Three studies have consistently demonstrated exercise
training to be cost-effective compared with usual care,
and have reported incremental cost effectiveness ratios
of $US 1,538 (1993 US dollars), $AUZ 4,986 (1997 Auz
dollars) and $NZ 1,803 (1998 NZ dollars) per fall pre-
vented respectively. However, there are limitations in
using these studies to inform current UK healthcare
policy on exercise in the management of Parkinson’s.
Firstly, all were conducted in an elderly community-
dwelling sample of participants and therefore have
uncertain generalisability to PwP. Secondly, given the
varying international patterns of healthcare utilisation,
the results may not directly applicable to UK. Finally,
Table 5 EQ-5D results at baseline, 10 and 20 weeks
Intervention
(n=48)
Control
(n=45)
Effect size (95% CI)*,
P-value
Baseline 0.70 (0.22) 0.65 (0.23)
10 weeks 0.66 (0.29) 0.66 (0.23) −0.04 (−0.12 to 0.05), P=0.395
20 weeks 0.74 (0.29) 0.62 (0.30) 0.08 (−0.03 to 0.19), P=0.131
*Adjusted for baseline EQ-5D score.
Table 6 QALYs and incremental cost effectiveness ratio at trial follow-up
Intervention
Mean (SD)
N=48
Control
Mean (SD)
N=45
Mean difference
Mean (95% CI),
P-value
ICER (£)
Cost
per QALY
QALYs 0.40 (0.13) 0.37 (0.12) 0.03 (−0.02 to 0.08), 0.32
Total healthcare costs (£) 1198 (1192) 1320 (1676) −128 (−734 to 478). 0.68 −4,885
Total health and social care costs (£) 1444 (1953) 1479 (1982) −35 (−817 to 746), 0.93 −1,358
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the scope of resource use costed in these studies was
limited, focusing on intervention costs and costs asso-
ciated with the prevention of falls rather than the full ex-
tent of healthcare costs.
Comparison with other research involving exercise to
reduce falls reveals a number of studies that have pro-
duced a mean cost per participant for a 1-year exercise
intervention in elderly populations. Three previous
studies have reported the mean costs of exercise inter-
ventions aimed at reducing falls in elderly populations.
Robertson et al. (2001) reported a cost per participant
for a home-based exercise intervention delivered by a
nurse to individual participants for three months
(followed by a three-month maintenance period) of
between $NZ 173 (£83) and $NZ 432 (£208) per pa-
tient [31,32]. Timonen et al. (2008) reported a cost
of 568 EUR (£583.54) per participant for a ten-week,
group-based exercise program for frail elderly women
after discharge from hospital following acute illness
[33], and Rizzo et al. (1996) reported $USD 905
(£582) per participant for a one-off, individually-
targeted falls prevention program for an elderly com-
munity population [28]. The cost of the one-off ten
week group exercise intervention therefore appears to
be relatively inexpensive to exercise interventions ap-
plied in previous evaluations of community-dwelling
elderly populations.
Strengths and weaknesses
This economic evaluation was set within a randomised
controlled trial. The aim was to examine the full scope
of health and social care resource use of participants on
the impact of the intervention for PwP at risk of falling.
Although every effort was made to collect all aspects of
healthcare resource use data for all randomised partici-
pants, difficulties were experienced in accounting for
some aspects of community-based primary care services.
This was due to a lack of routine recording of contacts
with physiotherapy, occupational therapy, speech ther-
apy, dietetics and community hospitals. As a result, con-
tacts with these services were omitted from the final
analyses. In addition, where it was not possible to collect
full data from aspects of health and social care, via rou-
tine records, such as contacts with community hospital
services, speech therapists and dietetics, these partici-
pants were excluded from the final analyses. Given the
older age of the participants in this study, we did not
deem it appropriate to peruse a fully societal perspective
and seek costs associated with lost productivity.
Participants with missing economic data at follow up
were found at have higher healthcare costs at entry to
this trial suggesting they have been more severe in their
disease and that our findings are subject to attrition
bias. However, those participants with missing and
complete data appeared balanced in terms of other
.
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Figure 1 Cost effectiveness acceptability curves for intervention based on QALY gains based on total healthcare costs and combined
total health and social care costs.
Fletcher et al. BMC Health Services Research 2012, 12:426 Page 7 of 9
http://www.biomedcentral.com/1472-6963/12/426
indicators of disease severity as according to Hoehn
and Yahr stage. Nevertheless this loss of data certainly
reduced overall statistical power to detect differences
in HRQoL and costs outcomes at follow up. Our find-
ings were robust to sensitivity analyses using two
methods of data imputation.
Cost-effectiveness is influenced by the time horizon
over which the analysis is evaluated. Shorter periods of
evaluation are often associated with less-favourable cost-
effectiveness, suggesting that perspectives motivated by
short-term gains may not see as much benefit from the
interventions that prevent longer-term morbidity and
premature mortality. The economic evaluation of the
GETuP trial examined resource use and cost over the
ten weeks of the intervention and a further ten weeks
during follow-up. Extended evaluation beyond this time
would provide evidence for any longer-term benefits of
the exercise intervention. As discussed earlier, there are
no such extrapolation studies in the area of exercise re-
habilitation for Parkinson’s. However, decision modelling
has been applied to more expensive drug therapies in
order demonstrate their potential cost-effectiveness over
the lifetime of the PwP [34]. Falls among PwP are asso-
ciated with carer burden [35], although we did not quan-
tify the impact on carers, in terms of HRQoL or lost
productivity. Carer burden of is a potentially important
area that deserves be considered in future economic
studies.
Reporting an incremental cost per QALY allows policy
makers to make comparisons between resource alloca-
tions for different medical conditions. It is recognised
however, that the EQ-5D, as a generic and not a
disease-specific instrument, may lack sufficient sensitiv-
ity to detect changes in HRQoL. The issue of the poten-
tial insensitivity of generic HRQoL measures was
highlighted by a recent systematic review of economic
evaluations of exercise interventions for reducing falls
in elderly populations [6]. Future research is needed to
better understand the relative sensitivity of disease-
specific HRQoL and generic measures such as the EQ-
5D in the Parkinson’s populations. A recently published
study has developed a mapping approach to link the
Parkinson’s disease Questionnaire (PDQ-39) to the
EQ-5D [36].
Conclusions
We know of no prior evidence on the cost-effectiveness
of an exercise-based intervention for PwP who are fre-
quent fallers. This study has shown the exercise inter-
vention to be relatively inexpensive and therefore likely
to be cost-effective if a small health gain can be shown.
Although results of the present study are supportive of
the cost-effectiveness of an exercise intervention target-
ing a reduction in falls, we recognise that this study may
be underpowered to make a definitive conclusion in
terms of the differences in costs and QALY between
groups. Larger scale economic evaluation studies are
therefore needed in order to affirm the findings of this
study before a definitive policy recommendation can be
made. In order to minimise bias, future economic eva-
luations should to be undertaken with the context of an
RCT, preferably with long term (≥ 12-months) follow-up
of outcome and costs. We are aware of ongoing research
in this area, such as two Australian trials of an eight-
week and six-month falls prevention exercise interven-
tion respectively for PwP [37,38].
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